**HematoLogics**

3161 Elliott Avenue, Suite 200, Seattle, WA 98121 Phone (800) 860-0934 Fax: (206) 223-5550 [www.hematologics.com](http://www.hematologics.com)

**AML MRD Identified by ∆N:**™(Difference from Normal) **Flow Cytometry at 0.04% confirmed by *FACS-FISH***

**Clinical History/Indications:** A patient with a clinical history of acute myeloid leukemia had a bone marrow aspirate submitted for Measurable Residual Disease(MRD) detection.



**Analysis/Conclusions:** The **∆:**™ ***Flow Cytometry*** findings reveal: 7.4% lymphocytes, 6.1% monocytes, 81% myeloid forms (all stages of maturation), 0.05% lymphoblasts, and 0.04% abnormal myeloid progenitor cells consistent with residual AML. Cell enrichment, by ***Fluorescent Activated Cell Sorting (FACS*),** of CD34 positive cells that included the abnormal cell population was followed by ***FISH*** *(****FACS-FISH****).*

****

***FACS-FISH***

***FISH (fluorescence in situ hybridization)* Result: Abnormal Monosomy 7**

Interphase FISH (fluorescence in situ hybridization) was performed using the D7S522/CEP 7 probe set to assess the CD34+ flow cytometric sorted cell population for the presence of monosomy 7. During the analysis of 200 interphase cells with the D7S522/CEP 7 probe set showed a 1R1G pattern (see image) in **25%** of the CD34+ cells examined, consistent with monosomy 7.

 **Best for Your Patient – Best for You**